Tuesday, May 29, 2007

VCU Behind New Blood-Clotting Product

VCU develops 'WoundStat'
Independent study by Army found product for troops' blood loss to be highly effective

Tuesday, May 29, 2007 - 12:01 AM


An explosion rips down an Iraqi street, spraying debris through the legs, torsos or arms of military troops.

In such a potentially fatal situation, seconds count when it comes to stopping blood loss. Those seconds and wounds may be filled by a substance created at Virginia Commonwealth University called WoundStat.

Smack a handful of the sandy mineral into a hemorrhaging wound, apply pressure, and the material forms a seal to stop the rapid blood loss. WoundStat has stopped lethal hemorrhaging within two minutes when tested on anesthetized pigs, the Army's model for such studies.

Until recently, methods for stopping heavy bleeding during combat had not changed much since the Civil War. Medics apply gauze and pressure or use a tourniquet to cut blood flow to limbs, which can result in amputations if left tied for too long.

For about a decade, the Army has been researching more high-tech ways to treat hemorrhaging.

"We looked at Vietnam, Korea, World War II. Of all those killed in action . . . about one-third to 40 percent died of bleeding to death," said Ronald R. Blanck, a retired surgeon general of the Army.

And most wounds, he notes, are treatable.

Soldiers overseas now carry the HemCon bandage, made with a blood-clotting agent derived from shrimp shells. A product called QuikClot does to blood what its name implies.

Then there's WoundStat. If it is approved by the U.S. Food and Drug Administration, Bethesda, Md.-based TraumaCure Inc. plans to sell the product to military and commercial customers.

WoundStat was developed in VCU Medical Center's Reanimation Engineering Shock Center.

"Our interest is in all things that have to do with critical illness and injury -- how to save the most critically ill and injured person and return them back to productive lives," said Dr. Kevin Ward, an emergency physician and associate director at the shock center.

Part of that group, called Operation Purple Heart, focuses on treating combat casualties.

"We took a step back and examined what the strengths and weaknesses were with the current [blood-stopping] products that were out there to see if there was something we could improve upon," Ward said. Research began in December 2004.

Ward and two colleagues -- biochemist Robert Diegelmann and biomedical engineer Gary Bowlin -- developed a tan-colored concoction of minerals that looks like a cross between flour, sand and cat litter. After its use, WoundStat can be peeled off the injury.

With the help of VCU's Office of Technology Transfer, the men were introduced to bioscience and entrepreneurial expert Jack McDonnell. Impressed by WoundStat's potential, McDonnell licensed the technology and established the company in May 2006. He is TraumaCure's chairman and executive vice president.

Chief Executive Officer Devinder S. Bawa and President and Chief Operating Officer Rhonda Friedman have expertise managing entrepreneurial and established health-care and technology firms.

"These three people have this combination of skills that are really required to make a company a success," said Ivelina Metcheva, director of VCU's tech transfer office, which works to spin out university research into products, services or businesses.

TraumaCure has landed "seven figures" worth of capital, McDonnell said, and it is seeking more. Money will be easier to find if talent is in place, Metcheva notes. "Venture capitalists bet on jockeys, not on horses."

McDonnell expects FDA approval before October, and then efforts go to selling to the military. The company also plans to market WoundStat to first responders such as emergency medical technicians, police and firefighters.

Blanck, the retired surgeon general and an outside director of TraumaCure, said current hemorrhage-stopping products -- specifically, HemCon and QuikClot -- have been a step in the right direction but that there is room for improvement.

"I'm not critical of them because I think they've been responsible for saving lives. Our goal is to save even more," he said. A spokeswoman for HemCon said its standard-issue bandages work best on large, high-blood flow wounds but are limited on smaller but serious injuries such as a gunshot. QuikClot clots blood but produces a reaction when used that creates excessive heat, and studies have found that it may damage organs and tissues.

An independent study by the Army's Institute of Surgical Research found WoundStat to be a highly effective wound dressing that does not produce a heat reaction. The report said the product's primary limitation is that it will stop blood flow on damaged vessels, acting as a granular tourniquet in areas where a traditional tourniquet cannot be tied, such as the groin. Such occlusion of the vessels could become a problem in a neck injury where blood must continue to flow.

The report also noted that more studies are needed to prove the product's efficacy and safety -- but Ward and his colleagues maintain it is harmless and lifesaving.

Should WoundStat hit the market, the VCU inventors will receive 40 percent of royalties on sales under terms of the university licensing agreements. The remaining 60 percent is disbursed across VCU.

"Not only is it great [business] potential, but look at what good it does in the world," McDonnell said. "It's fabulous."

Wednesday, May 23, 2007

New Lab Space for NoVa?

Developer plots NoVa lab space to attract biotechs
Washington Business Journal - May 11, 2007
by Vandana Sinha
Staff Reporter

After years of coming up dry, Northern Virginia is winning new wet lab space.

The area -- long lambasted for lacking the lab space that could attract a vibrant biotech community -- may be seeing early signs of a long-term turnaround with new plots of lab-worthy land.

Pasadena, Calif.-based Alexandria Real Estate Equities, a leading national lab property owner and developer, is in preliminary plans to market a new 20-acre stretch of research and development land near George Mason University at Innovation @ Prince William Technology Business Park.

Meanwhile, Rockville-based Scheer Partners is helping develop a 50-acre section of the Innovation park for tech and biotech prospects. The local real estate firm also recently began marketing 35,000 square feet of empty office and lab space in a Chantilly office park building.

In addition, when pharmaceutical giant Eli Lilly pulled out of its $325 million development deal in January, the company left Northern Virginia with 10,000 square feet of lab space about six miles from Prince William's Innovation park, where its half-built insulin manufacturing plant still sits on 120 acres now back on the market.

The combination has area leaders excited about starting to bridge one of the chasms separating them from a successful biotech community. But they may need to remain patient. Much of that lab space is, or likely will be, fit only for larger tenants with deeper pockets, forcing biotech startups to keep hunting for smaller headquarters along Interstate 270 in Maryland.

"What happens down in Prince William County will, I think, be the bellwether," says Dan Gonzalez, executive vice president in Scheer Partners' McLean office. "There will be a vibrant biotech community in Northern Virginia, but it won't look anything like Maryland. The 2,000- to 5,000-square-feet startups won't be in Northern Virginia for a long time."

Most of that comes down to economics, Gonzalez says.

With the high costs of building lab space from scratch, developers get more payoff from a larger, established tenant willing to snatch up 30,000 square feet at a time, rather than from the risky startups that can only afford one-tenth of that for their first several years.

The question is: How many of those larger biotechs are eyeing Northern Virginia?

So far, for its 35,000-square-foot Chantilly lab space at Avion Business Park -- former federal government quarters that can't be physically subdivided into smaller pieces for startup companies -- Scheer Partners has found more "tire-kickers" than tenants.

Scheer Partners is in talks with an undisclosed New Jersey cell-therapy diagnostics company that needs 20,000 to 60,000 square feet, Gonzalez says. But he adds, until public or private entities put their dollars toward incubator space for startups, demand for Northern Virginia lab space could remain slow.

At Prince William County's 50-acre Waterford Development plot, which Scheer is helping develop, there is room for 1 million square feet of office and lab space. But the developers say market demand calls for building only 650,000 square feet.

Alexandria Real Estate also says it doesn't plan any lab construction until it scores some tenants. It is aiming for a single, sizable company to fill up its 20-acre plot, originally 40 acres before it sold 10 acres apiece to the neighboring George Mason University biocontainment lab and Virginia Department of Forensic Science lab, both poised to break ground within weeks.

"A big part of this is where we see the market demand," says Jim Richardson, president of Alexandria Real Estate, which has an office in Gaithersburg. "This is an emerging market. It's at an embryonic stage. So we're going to be very careful and prudent when we move through this."

Both real estate parties could find a customer in George Mason. The university's leaders expect to issue a request for proposals by the fall to lease a projected 10,000 to 30,000 square feet of lab space for faculty research, now crowded into the Prince William and Fairfax campus labs.

But the university, whose own biotech spinoff Theranostics Health was shipped to Rockville in March for lack of Northern Virginia lab space, says it is also discussing whether to include an incubator setting in its proposed space to help those startups and future spinoffs.

"Is there demand out there for companies to lease 1,000 square feet? I think there is. Are there 30 of them? Probably not," says Jerry Coughter, assistant vice president for regional economic development at George Mason University. "That's part of the quandary that developers are in."